Loading candles…
Syngene International Ltd., established in 1993 as a subsidiary of Biocon, operates as an integrated contract research, development, and manufacturing organization. It provides end-to-end drug discovery, development, and manufacturing services (CRAMS) on a single platform. The company caters to multiple industries including pharmaceuticals, biotechnology, nutrition, animal health, consumer goods, and specialty chemicals. Syngene offers a range of services such as drug discovery and development services, manufacturing services, and scientific services spanning the entire drug discovery and development value chain. Notably, it is recognized as India's first Contract Research Organization (CRO). The company supports global pharmaceutical and biotechnology firms as a strategic partner. Its research and manufacturing facilities cover approximately 1.9 million square feet and employ a workforce of over 5,600 scientists.
| Date |
|---|
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 and dividend | 29 Apr 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 22 Jan 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 5 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 23 Jul 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and dividend | 23 Apr 2025 |
Besseggen InfoTech LLP is a SEBI-registered stock broker (Reg. No. INZ000213450), member of NSE (90155 (Cash & F&O)) and BSE (6722 (Cash & F&O)). Investment in securities market are subject to market risks; read all related documents carefully before investing.